REGN7544

Phase 2Small molecule

Regeneron

REGN7544 is one of 45 small molecule programs targeting Tachycardia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TachycardiaActive, not recruiting

HypotensionActive, not recruiting

TachycardiaPhase 2

Active, not recruiting

HypotensionPhase 2

Active, not recruiting

Competition

Competitive Landscape

136 competitors in Hypotension

#DrugCompanyPhaseTrials

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 3

34 2

Firazyr

Takeda

Phase 3

1 3

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

3 4

Midodrine Hydrochloride

Takeda

Phase 3

1 5

Noradrenaline

IInstitute of Liver and Biliary Sciences, India

Phase 3

2 6

L-Carnitine

IIperboreal Pharma Srl

Phase 3

1 7

Bronitin Mist

LLongeveron Inc.

Phase 3

2 8

Voluven

RRegional Hospital Holstebro

Phase 3

3 9

Hemospan (MP4OX)

SSangart

Phase 3

2 10

Metaraminol

UUniversity of Sao Paulo General Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypotension1 trial

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT06608901·76 enrolled

Tachycardia1 trial

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT06593600·81 enrolled

Adult1 trial

A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

Completed· Regeneron logo

Regeneron·Phase 1·NCT05970718·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for REGN7544. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN7544 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN7544. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

REGN7544

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypotension1 trial

Tachycardia1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News